Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Feb:55:137.
doi: 10.1016/j.breast.2020.11.011. Epub 2020 Nov 21.

Reply to Letter to Editor: "HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?"

Shuai Li  1 , Xiaosong Chen  2
Affiliations
Comment

Reply to Letter to Editor: "HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?"

Shuai Li et al. Breast. 2021 Feb.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Ryden L., Landberg G., Stal O., Nordenskjold B., Ferno M., Bendahl P.O. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information. Breast Canc Res Treat. 2008;109:351–357. - PubMed
    1. Montemurro F., Di Cosimo S., Arpino G. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. Ann Oncol. 2013;24:2715–2724. - PubMed
    1. García Fernández A., Giménez N., Fraile M., González S., Chabrera C., Torras M. Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. a single institution survey spanning 1998 to 2010. Breast. 2012;21:366–373. - PubMed
    1. Goutsouliak K., Veeraraghavan J., Sethunath V. Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol. 2020;17(4):233–250. - PMC - PubMed
    1. Li S., Wu J., Huang O., He J., Zhu L., Chen W. HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab. The Breast. 2020 doi: 10.1016/j.breast.2020.10.002. 0. - DOI - PMC - PubMed

Substances